G6PD deficiency is a common and X-linked enzymopathy affecting approximately 400 million people. G6PD mutations are carried by females, with 90% of males with the genetic defect being affected. These affected individuals suffer from a hemolytic crisis after being exposed to oxidants or microbes, including coronaviruses [9–11]. Geographically, G6PD deficiency affects individuals in African, Mediterranean, Southeast, and South Asian, and Latin American countries. The fact that G6PD deficiency is more common in some European countries, like Italy and Spain along with the fact that these Mediterranean countries are severely affected by COVID-19 pandemic and have high fatality rates may not be coincidental [12,13]. This raises the spectre that “G6PD deficiency” can be a predisposing factor that causes severe COVID-19 illness [14]. This review aims to discuss the potential link between G6PD and viral infections including COVID-19 from the standpoint of redox homeostasis. The alternative therapies for COVID-19, including antioxidants and anti-aging drugs are also discussed.